Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Xenobiotic Detection Systems (XDS) is a specialized bioanalytical company based in Durham, North Carolina, that provides advanced screening services for toxic chemicals and endocrine disruptors. The company is best known for its proprietary CALUX (Chemically Activated LUciferase eXpression) cell-based assay system, which is used to detect dioxins, polychlorinated biphenyls (PCBs), and other xenobiotics that interact with specific cellular receptors. XDS serves clients in the environmental, food safety, and pharmaceutical industries by offering high-throughput screening for aryl hydrocarbon receptor (AhR) and steroid hormone receptor ligands. Their technology provides a cost-effective and rapid alternative to traditional high-resolution gas chromatography/mass spectrometry (HRGC/MS) for monitoring environmental contaminants. The company's assays are utilized globally for regulatory compliance and safety assessment of chemicals in various matrices.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Xenobiotic Detection Systems.